Uni-Bio Science Group Ltd. (690) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

China Isotope & Radiation Corp.

PW Medtech Group Ltd.

Uni-Bio Science Group Ltd.

Essex Bio-Technology Ltd.

Beijing Chunlizhengda Medical Instruments Co., Ltd.

Zylox-Tonbridge Medical Technology Co., Ltd.

Sisram Medical Ltd.

Shanghai Heartcare Medical Technology Corp. Ltd.

Shanghai Conant Optical Co., Ltd.

Broncus Holding Corp.

Venus Medtech (Hangzhou), Inc.

Why is Uni-Bio Science Group Ltd. ?

High Management Efficiency with a high ROE of 14.78%

Strong Long Term Fundamental Strength with a 26.84% CAGR growth in Net Sales

Healthy long term growth as Net Sales has grown by an annual rate of 26.84%

The company declared negative results in Dec'24 after positive results in Jun'24

INTEREST(HY) At HKD 0.92 MM has Grown at 159.55%
DEBT-EQUITY RATIO (HY) Highest at -16.8 %
INTEREST COVERAGE RATIO(Q) Lowest at 3,798.81

With ROE of 25.42%, it has a Very Attractive valuation with a 2.90 Price to Book Value

Over the past year, while the stock has generated a return of 72.73%, its profits have risen by 16.8% ; the PEG ratio of the company is 0.5
At the current price, the company has a high dividend yield of 186.9

Market Beating Performance

The stock has generated a return of 72.73% in the last 1 year, much higher than market (Hang Seng Hong Kong) returns of 26.67%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Uni-Bio Science Group Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Uni-Bio Science Group Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Uni-Bio Science Group Ltd.

75.38%

1.07

70.67%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

26.84%

EBIT Growth (5y)

31.59%

EBIT to Interest (avg)

25.14

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

1.63

Tax Ratio

6.39%

Dividend Payout Ratio

20.52%

Pledged Shares

Institutional Holding

ROCE (avg)

22.26%

ROE (avg)

14.78%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.90

EV to EBIT

9.39

EV to EBITDA

7.65

EV to Capital Employed

3.36

EV to Sales

1.59

PEG Ratio

0.47

Dividend Yield

186.87%

ROCE (Latest)

35.84%

ROE (Latest)

25.42%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Uni-Bio Science Group Ltd.

Operating Cash Flow

Highest at HKD 168.29 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Net Sales

Highest at HKD 279.37 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Cash and Eqv

Highest at HKD 169.89 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Dividend Payout Ratio

Highest at 106.54%

in the last five years

MOJO Watch

Company is distributing higher proportion of profits generated as dividend

DPR (%)

Raw Material Cost

Fallen by -6.65% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Uni-Bio Science Group Ltd.

Interest

At HKD 0.92 MM has Grown at 159.55%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Interest Coverage Ratio

Lowest at 3,798.81

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Debt-Equity Ratio

Highest at -16.8 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Profit Margin

Lowest at 12.56 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at HKD 16.89 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Net Profit

Lowest at HKD 15.39 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (HKD MM)

EPS

Lowest at HKD 0

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (HKD)

Debtors Turnover Ratio

Lowest at 5.9%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio